Diffusion Pharmaceuticals : DFFN Corporate Presentation - 3Q 2022 NC

Corporate Presentation

Third Quarter 2022

NON-CONFIDENTIAL

www.diffusionpharma.com

1

Note Regarding Forward-Looking Statements

This presentation (including, for purposes of this Note Regarding Forward-Looking Statements, any accompanying or supplemental oral presentation) includes express and implied forward- looking statements relating to: our product candidates and pipeline; our corporate strategy and product development plans; the prospects and potential of our business and our product candidates, including their safety, effectiveness, and commercial prospects; our anticipated clinical trials, other studies, and the timing and substance of data readouts therefrom; certain regulatory matters; business development activities, including potential collaborations; certain matters regarding our financial results and securities; milestones, timing, and other expectations regarding any of the foregoing; and any other matter that is not a statement of historical fact, including statements regarding our intentions, beliefs, projections, outlook, analyses, or expectations. We may, in some cases, use terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

By their nature, forward-looking statements relate to events, competitive dynamics, and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated, and therefore inherently involve risks and uncertainties, including those discussed under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, as a result of these and other factors, known and unknown, actual results could differ materially from our intentions, beliefs, projections, outlook, analyses, or expectations expressed in any forward-looking statements in this presentation. Accordingly, we cannot assure you that the forward-looking statements contained in this presentation will prove to be accurate or that any such inaccuracy will not be material, and you should not place undue reliance on such statements.

Unless the context requires otherwise, all forward-looking statements that we make in this presentation are based on our beliefs and expectations as of, and speak only as of, the first date set forth on the cover page hereof and, except as required by applicable law or by the rules and regulations of the SEC, we undertake no obligation to update such statements to reflect events or circumstances after such date.

Certain information contained in this presentation relates to or is based on studies, publications, surveys, and other data derived from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involve a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, although we believe our own internal research is reliable, such research has not been verified by any independent source.

2

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) is a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to the areas where it is needed most.

Our lead drug candidate, trans sodium crocetinate (TSC), has broad potential to treat the many conditions complicated by hypoxia.

3

Trans Sodium Crocetinate (TSC)

A novel, bipolar synthetic carotenoid designed to enhance the oxygenation of hypoxic tissues.

Sodium salt of the trans isomer of crocetin, which is derived from saffron - only the trans isomer modifies oxygen diffusivity.

TSC enhances diffusion of oxygen through blood by creating a less dense matrix of water molecules in the blood plasma, opening more direct pathways for movement down the gradient.

4

TSC enhances oxygen movement through the blood, facilitating oxygen diffusion into tissues

5